Ebola outbreak accelerates: cases jump 40% in a week across DR Congo and Uganda, death toll passes 200
An Ebola outbreak unfolding across northern Democratic Republic of Congo and western Uganda accelerated measurably in the past week. According to the World Health Organization's 18 June update, confirmed cases rose from roughly 300 the previous week to more than 420, a jump of about 40% — among the steepest single-week increases since the outbreak was declared.
The official death toll now stands at 207. The WHO cautioned that the true figure is likely higher "because of unreported cases." The agency repeated earlier warnings that the current cross-border outbreak could be the largest regional Ebola event since the 2014-16 West Africa epidemic.
The densest clusters of transmission are around Beni and Butembo in North Kivu province, with new border-linked cases reported in Kasese and Bundibugyo districts on the Ugandan side. Field teams cited by STAT News say contact tracing is breaking down in areas where armed groups are active.
The US Centers for Disease Control and Prevention announced earlier this week that it would release $107 million in emergency funds. Most of it will pay tracing teams in Congo, replenish laboratory reagents and reinforce screening posts on the Ugandan border.
Vaccine supply is back in focus. The WHO-coordinated Ebola vaccine stockpile reported access to about 380,000 doses, constrained by cold-chain logistics and the production schedule of the manufacturer. Field workers say they have so far been able to maintain the daily doses needed for "ring vaccination" along confirmed contact chains.
A second priority is protecting health workers. According to a STAT News report last week, some treatment centres in Beni are running 24-hour shifts because reserve staff are not arriving. A regional health workers' union said the patient load per trained nurse is nearly double what it was during the previous outbreak.
Experts continue to stress that the global risk of spread remains low. Ebola transmits only through contact with bodily fluids, not respiratory droplets, which sets it apart from outbreaks such as COVID-19 or influenza. Even so, screening and notification protocols at international airports have been activated as a drill.
Famine and displacement in the region last year had already weakened local health infrastructure. The WHO's regional director described the outbreak this week by saying that "Ebola is not a standalone disease — it is layered on top of a broader crisis."
WHO Director-General Tedros Adhanom Ghebreyesus, returning last week from a visit to DRC, said armed conflict in the affected zone was "a larger obstacle than Ebola itself." Field teams report that sample transport is delayed by days in some areas when routes are controlled by armed groups.
WHO technical teams view the next ten days as the critical window in which the case curve must bend. CDC modelling suggests that, at the present response intensity, cumulative cases could peak between 5,000 and 8,000 within four months; under more aggressive vaccination and tracing scenarios, that figure could fall substantially.
Read next
Do humans have hidden regenerative powers? What the new research says
Science Daily covers new research showing that humans carry the same regeneration genes that drive limb regrowth in salamanders and axolotls — but kept silent in normal conditions. The finding could reshape the trajectory of regenerative medicine.
Think you're eating healthy? You may be missing this heart-protecting nutrient
A new Tufts University study reports that a large share of adults who consider their diet healthy fall short on omega-3 intake — the nutrient most strongly linked to heart protection. The researchers say fish, leafy greens and walnuts close the gap.
Kidney cancer rates near Pfas factory in Lancashire flagged as 'major source of concern'
A study reported by the Guardian shows that kidney cancer rates around a Pfas-producing factory in Lancashire have run above the UK average for two decades. The findings reignite the debate over how Britain regulates 'forever chemicals'.
Cambrian's experimental longevity drug mimics exercise: what the first human data show
In an early human study run by Cambrian Bio, an experimental molecule activated mitochondrial genes and produced blood-marker changes that mimic the effects of exercise. STAT News explains what the data show — and the questions that remain.
Do wearables actually help people with cardiovascular disease? What the latest evidence says
Smart watches and rings now routinely track steps, heart rhythm and sleep. STAT News reviews recent meta-analyses showing where wearables produce measurable clinical benefit for people with cardiovascular disease — and where the evidence still falls short.
